Abstract Library

#3073 The Role of Rb as a Prognostic Factor in Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (G3NEC) Treated by First Line Platinum-Etoposide Combination, a Retrospective Study

Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,

Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,

#2730 FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling

Introduction: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Afchain P, Walter T, Tougeron D, Hautefeuille V,

Keywords: neuroendocrine carcinoma, gastroenteropancreatic, chemotherapy, FOLFIRINOX, RB,

#2699 Dacarbazine- or Temozolomide-Based Chemotherapy in Metastatic Digestive Neuroendocrine Carcinomas in Post First-line Chemotherapy: A Retrospective Multicentric Study of the French Group of Endocrine Tumours (GTE)

Introduction: First-line chemotherapy in metastatic neuroendocrine carcinomas (NEC) is based on etoposide and platinum. However, there is no standard for second line treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Walter T

Authors: Couronne T, Fine C, Hadoux J, Lecomte T, Lorcet M,

Keywords: neuroendocrine, poorly differentiated neuroendocrine tumour, neuroendocrine carcinoma, chemotherapy, temozolomide, dacarbazine,

#1845 Mismatch Repair (MMR) Protein Expression is Uncommon in Poorly Differentiated Neuroendocrine Carcinoma

Introduction: Microsatellite instability (MSI) has been reported to occur in a significant proportion of neuroendocrine carcinoma (NEC) and mixed adenoneuroendocrine carcinomas (MANEC) (11 out of 89 cases, Sahnane et al, ERC 2015). It might be predictive of response to immunotherapy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hadoux J

Authors: Hadoux J, Malka D, Berdeloux A, Planchard D, Boige V,

Keywords: Neuroendocrine carcinoma, mismatch repair, microsatellite instability,

#1672 PD-L1 Expression and Quantitative Assessment of Tumor-Infiltrating T Cell Subsets in Carcinoid Tumors and Large Cell Neuroendocrine Carcinomas of the Lung

Introduction: Little is known about the expression of PD-L1 an the immune infiltrate in neuroendocrine neoplasms of the lung.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Julien H

Authors: Kossai M, Hadoux J, Louvet E, Sullivan I, Thomas de Montpreville V,

Keywords: PD-L1, lung, neuroendocrine, immune infiltrate.,